

public payors are looking to improve efficiency of processes, prioritization of drugs, cost containment of cancer care and increase access to innovative medicines. championing a strong biosimilar market in canada through policies that encourage uptake, ongoing education for key stakeholders along with the concept of gainsharing, in which cost savings from the use of biosimilars are reallocated to improve overall health system outcomes, will be beneficial to all stakeholders.
biosimilar pegfilgrastim. improving access and optimising practice to supportive care that enables cure
biosimilar medicines can significantly reshape access to innovative cancer therapies. infographic
colab.february 2020
CADTH technology 360 review. optimal use report
CADTH technology review. optimal use 360 report
biosimilar drugs to provide safe, effective treatment
shifting biosimilar access policies to promote fiscal sustainability in the canadian healthcare system
medicines for europe. position statements on physician led switching for biosimilars [EU]
biosimilars regulation in canada. state of play
an ever evolving landscape. an update on the rapidly changing regulation and reimbursement of biosimilars in canada
position of scientific oncological societies towards biosimilars
biosimilars in canada. current and future opportunities
advancing biosimilar sustainability in europe- IQVIA Report
colab webinar series : biosimilars. the european experience
payor perspective
June 19, 2019 11:00 am in eastern time (US and Canada)
View recorded webinar
policy perspective
details for registration coming shortly
health care provider perspective
details for registration coming shortly
CADTH program updates on biosimilars
as of june 1, 2019, CADTH will be stopping work on any biosimilar reviews that would have been completed after june 1, 2019.
update : cadth pharmaceutical review- issue 8
breast cancer & biosimilars from the canadian breast cancer network
access whitepaper
pan-canadian oncology biosimilars initiative
this biosimilars initiative aims to ensure that the implementation and use of therapeutic oncology biosimilars are appropriate and cost-effective across canada and is jointly supported by the pan-canadian pharmaceutical alliance and managed by cancer care ontario on behalf of all provincial cancer agencies.
website link
map for implementing oncology biosimilars across canada.
biosimilars action report
biosimilar biologic drugs in canada. fact sheet health canada
health canada authorizes biosimilars for sale using the same rigorous regulatory standards for quality, efficacy and safety as for all other biologic drugs.
the cancer collaborative biosimilars initiative is supported with funding by the following organizations
